Mei Wei
( out of 210 reviews )

Mei Wei, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital North

2K, Plastic and Reconstructive Surgery
Salt Lake City

  • Dr. Wei Mei is specialized in breast medical oncology. Her research interests focus on clinical trials, breast cancer outcome research, epidemiology and patient's quality of life.

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 210 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    March 20, 2025
    SUGAR HOUSE HEALTH CENTER

    She was thorough and thoughtful and knew what care I would need and what is good about referring me for tests that I needed to have repeated.

    March 20, 2025
    SUGAR HOUSE HEALTH CENTER

    Mei Wei is an exceptional doctor and a precious person! I always feel cared about and listened to! She is fantastic!!! I wish her all the best in her practice! You can't go wrong using her!!!

    March 14, 2025
    HUNTSMAN CANCER CENTER

    She is the best. She has treated me for 3 years and I would recommend her to anyone

    March 01, 2025
    HUNTSMAN CANCER CENTER

    I'm so thankful for Dr. Wei. I reached out to her for a breast concern, and she was able to promptly get me into be examined. I will never be ever to thank you enough for listening to my concerns and being so caring and compassionate.

    February 27, 2025
    SUGAR HOUSE HEALTH CENTER

    Very nice and positive attitude

    February 19, 2025
    HUNTSMAN CANCER CENTER

    I have recommended Dr. Wei to other women because she is a great oncologist, but also very good at listening to me and addressing my questions and concerns. I feel very safe in her care.

    February 14, 2025
    HUNTSMAN CANCER CENTER

    very efficient

    December 20, 2024
    HUNTSMAN CANCER CENTER

    Dr. Wei is caring and thorough. She listens and asks the right questions.

    December 11, 2024
    SUGAR HOUSE HEALTH CENTER

    Very knowledgeable, was familiar with my case before my appointment. Explained things clearly. I feel confident in her care.

    See More Patient Comments

  • Dr. Wei Mei is specialized in breast medical oncology. Her research interests focus on clinical trials, breast cancer outcome research, epidemiology and patient's quality of life.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology/Oncology - University of Utah School of Medicine Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Internship Internal Medicine - University of Nevada, Reno School of Medicine Intern
    Research Fellow Cancer Epidemiology - University of Utah School of Medicine Postdoctoral Research Fellow
    Residency Radiation Oncology - Sun Yat-sen University Cancer Center Resident
    Residency Gynecological Oncology - Sun Yat-sen University Cancer Center Resident
    Professional Medical Medicine - Anhui Medical University M.D.

    Selected Publications

    Journal Article

    1. Howell JN, Mark B, Wada DA, Bowling M, Wei M, Lloyd SL, Gaffney DK, Maity A, LaRiviere MJ, Rule WG, Grant JD, Deshmukh V, Newman M, Date A, Hashibe M, Tao R (2025). Mental Health Diagnoses in Patients With Mycosis Fungoides and Potential Impact on Oncologic Outcomes. Cancer Med, 14(5), e70577. (Read full article)
    2. Keefe K, McCrary HC, Wei M, Mark B, Drejet S, Cannon RB, Buchmann LO, Hunt JP, Dodson M, Deshmukh V, Newman M, Monroe MM, Hashibe M (2024). Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study. Oral Oncol, 159, 107041. (Read full article)
    3. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Bailey J, Burstein HJ, Chen N, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, McCloskey S, McShane M, Mortimer J, Patel SA, Rosenberger LH, Rugo HS, Santa-Maria C, Schneider BP, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Yeung KT, Young JS, Schonfeld R, Kumar R (2024). Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 22(5), 331-357. (Read full article)
    4. Vaklavas C, Matsen CB, Chu Z, Boucher KM, Scherer SD, Pathi S, Beck A, Brownson KE, Buys SS, Chittoria N, DAstous E, Gulbahce HE, Henry NL, Kimani S, Porretta J, Rosenthal R, Ward J, Wei M, Welm BE, Welm AL (2024). TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO Precis Oncol, 8, e2300724. (Read full article)
    5. Koric A, Chang CE, Lee YA, Wei M, Lee C, Tao R, Wang J, Tay D, Hashibe M (2024). Incident Diabetes among Older Asian, Native Hawaiian and Pacific Islander Women with Breast Cancer. JNCI Cancer Spectr, 8(4). (Read full article)
    6. NCCN breast oncology panel (2024). NCCN clinical practice guidelines in oncology, Breast Cancer. Version 1.2024. J Natl Compr Canc Netw.
    7. Hashibe M, Wei M, Lee CJ, Tao R, Koric A, Wang J, Daud A, Tay D, Shen J, Lee YA, Chang CE (2023). Incident Cardiovascular Disease Risk among Older Asian, Native Hawaiian and Pacific Islander Breast Cancer Survivors. Cancer Epidemiol Biomarkers Prev, 33(1), 126-135. (Read full article)
    8. Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap JT (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol, 221(2), 228-239. (Read full article)
    9. Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch AM, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Schneider B, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Wei M, Wisinski KB, Young JS, Yeung K, Dwyer MA, Kumar R (2023). NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw, 21(6), 594-608. (Read full article)
    10. Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, theMednetorg NCI-CCC Tumor Board Program Collaborative Group, Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N (2022). Making National Cancer Institute-Designated Comprehensive Cancer Center Knowledge Accessible to Community Oncologists via an Online Tumor Board: Longitudinal Observational Study. JMIR Cancer, 8(2), e33859. (Read full article)
    11. Sharma A, Johnson KB, Bie B, Rhoades EE, Sen A, Kida Y, Hockings J, Gatta A, Davenport J, Arcangelini C, Ritzu J, DeVecchio J, Hughen R, Wei M, Thomas Budd G, Lynn Henry N, Eng C, Foss J, Rotroff DM (2022). A Multimodal Approach to Discover Biomarkers for Taxane-Induced Peripheral Neuropathy (TIPN): A Study Protocol. Technol Cancer Res Treat, 21, 15330338221127169. (Read full article)
    12. Wei M, Wang X, Zimmerman DN, Burt LM, Haaland B, Henry NL (2021). Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer. Breast Cancer Res Treat, 187(1), 287-294. (Read full article)
    13. Bernard PS, Wooderchak-Donahue W, Wei M, Bray SM, Wood KC, Parikh B, McMillin GA (2021). Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer. Cancers (Basel), 13(6). (Read full article)
    14. Gilreath JA, Wei M, Paul S, Parker CJ, Stenehjem DD, Rodgers GM (2018). Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports. J Oncol Pharm Pract, 25(3), 719-723. (Read full article)
    15. Raspanti GA, Hashibe M, Siwakoti B, Wei M, Thakur BK, Pun CB, Al-Temimi M, Lee YC, Sapkota A (2016). Household air pollution and lung cancer risk among never-smokers in Nepal. Environ Res, 147, 141-5. (Read full article)
    16. Raspanti GA, Hashibe M, Siwakoti B, Wei M, Thakur BK, Pun CB, Milrod C, Adhikari S, Lee YC, Sapkota A (2015). Ethnic Variation in Consumption of Traditional Tobacco Products and Lung Cancer Risk in Nepal. Asian Pac J Cancer Prev, 16(14), 5721-6. (Read full article)

    Review

    1. Johnson KB, Sharma A, Henry NL, Wei M, Bie B, Hershberger CE, Rhoades EE, Sen A, Johnson RE, Steenblik J, Hockings J, Budd GT, Eng C, Foss J, Rotroff DM (2023). Genetic variations that influence paclitaxel pharmacokinetics and intracellular effects that may contribute to chemotherapy-induced neuropathy: A narrative review. [Review]. Front Pain Res (Lausanne), 4, 1139883. (Read full article)

    Case Report

    1. Wei M, Maurer KA, Henry NL (2019). Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy. Breast J, 25(6), 1254-1256. (Read full article)